1. Walker LE, FitzGerald R, Saunders G, Lyon R, Fisher M, Martin K, et al. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. Clin Pharmacol Ther. 2022 Mar;111(3):585-94.
  2. Sacramento CQ, Fintelman-Rodrigues N, Dias SSG, Temerozo JR, Da Silva APD, da Silva CS, et al. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. Viruses. 2022 Feb 11;14(2).
  3. Sae-Heng T, Rajoli RKR, Siccardi M, Karbwang J, Na-Bangchang K. Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):104-15.
  4. Pertinez H, Rajoli RKR, Khoo SH, Owen A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. J Antimicrob Chemother. 2021 Jul 15;76(8):2121-8.
  5. Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias S, da Silva CDS, et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021 Jun 18;76(7):1874-85.
  6. Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, et al. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. Br J Clin Pharmacol. 2021 Apr;87(4):2078-88.
  7. Pertinez H, Rajoli RKR, Khoo SH, Owen A. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. J Antimicrob Chemother. 2021 Jul 15;76(8):2121-8.
  8. Saeheng T, Na-Bangchang K, Siccardi M, Rajoli RKR, Karbwang J. Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. Clin Pharmacol Ther. 2020 May;107(5):1209-20.
  9. Rajoli RKR, Demkovich ZR, Flexner C, Owen A, Siccardi M. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. Antimicrob Agents Chemother. 2020 Jul 22;64(8).
  10. Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother. 2020 Mar 1;75(3):640-7.
  11. Rajoli RKR, Flexner C, Chiong J, Owen A, Donnelly RF, Larraneta E, et al. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. Eur J Pharm Biopharm. 2019 Nov;144:101-9.
  12. Rajoli RKR, Curley P, Chiong J, Back D, Flexner C, Owen A, et al. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. J Infect Dis. 2019 May 5;219(11):1735-42.
  13. Atoyebi SA, Rajoli RKR, Adejuyigbe E, Owen A, Bolaji O, Siccardi M, et al. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. Eur J Pharm Sci. 2019 Dec 1;140:105068.
  14. Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher CV, et al. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. J Antimicrob Chemother. 2018 Apr 1;73(4):1004-12.
  15. Rajoli RKR, Podany AT, Moss DM, Swindells S, Flexner C, Owen A, et al. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):937-44.
  16. Rajoli RKR, Back DJ, Rannard S, Meyers CF, Flexner C, Owen A, et al. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. Clin Pharmacokinet. 2018 Feb;57(2):255-66.
  17. Molto J, Rajoli R, Back D, Valle M, Miranda C, Owen A, et al. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. J Antimicrob Chemother. 2017 Mar 1;72(3):805-11.
  18. Marzolini C, Rajoli R, Battegay M, Elzi L, Back D, Siccardi M. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clin Pharmacokinet. 2017 Apr;56(4):409-20.
  19. Curley P, Rajoli RK, Moss DM, Liptrott NJ, Letendre S, Owen A, et al. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrob Agents Chemother. 2017 Jan;61(1).
  20. Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, et al. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clin Pharmacokinet. 2015 Jun;54(6):639-50.